Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCKDK | O14874 | 2/20 | 0.57 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
| ▸ | TLR3 | O15455 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25224912 | 0.88 | BCKDK (0.50) | BCKDKSENP1MCL1STING1DHODH | |
| SCHEMBL25205701 | 0.87 | BCKDK (0.52) | BCKDKSENP1MCL1BCL2L1LMNA | |
| SCHEMBL25209826 | 0.85 | BCKDK (0.56) | BCKDKSENP1MCL1BCL2L1LMNA | |
| SCHEMBL25205688 | 0.84 | BCKDK (0.57) | BCKDKSENP1MCL1BCL2L1LMNA | |
| SCHEMBL25204361 | 0.84 | BCKDK (0.45) | BCKDKSENP1MCL1ALDH1A1RXFP1 | |
| SCHEMBL25216954 | 0.83 | BCKDK (0.53) | BCKDKSENP1MCL1BCL2L1LMNA | |
| SCHEMBL25225314 | 0.83 | MCL1 (0.49) | BCKDKMCL1BCL2L1LMNAALDH1A1 | |
| SCHEMBL25204605 | 0.81 | BCKDK (0.50) | BCKDKMCL1BCL2L1LMNARAB9A | |
| SCHEMBL25233524 | 0.81 | BCKDK (0.50) | BCKDKMCL1BCL2L1LMNARAB9A | |
| SCHEMBL25217785 | 0.80 | BCKDK (0.64) | BCKDKSENP1MCL1BCL2L1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | BCKDK 1/4885SENP1 2060/4885MCL1 2996/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | BCKDK 1/4885SENP1 2060/4885MCL1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.